Nuvaxovid COVID-19 vaccine receives expanded authorization in Canada .- Novavax.
Novavax, Inc., announced that Health Canada has granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older.
The expanded authorization was based on data from a Phase II trial conducted in South Africa and from the Prevent-19 Phase III trial conducted in the U.S. and Mexico. As part of the trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six to 11 months after their primary series of two doses administered three weeks apart. The third (booster) dose produced increased immune responses to levels comparable to or exceeding those associated with protection against COVID-19 in Phase III clinical trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.